Close Menu

multiple myeloma

The company plans to offer about 3.2 million shares of its common stock at $2.80 per share. 

The FDA conditionally approved the microarray-based gene expression test for use as entry criteria for a clinical trial for an investigational new drug for multiple myeloma. 

GNS Healthcare and the Multiple Myeloma Research Foundation to use GNS' informatics solutions to explore genomic and clinical data from the CoMMpass study.

Cancer Genetics CEO Panna Sharma told GenomeWeb this week that the company plans to focus on very targeted panels of actionable mutations.

Using a combination of proteomic approaches, researchers from Boston's Brigham and Women's Hospital, the Broad Institute, and the Dana-Farber Cancer Institute have identified the mechanism of action of the multiple myeloma drug lenalidomide.

NEW YORK (GenomeWeb News) – Empire Genomics today said that its clinical laboratory facility has received CLIA certification and has been approved by the New York State Department of Health.

NEW YORK (GenomeWeb News) – Signal Genetics today said that Arkansas Blue Cross Blue Shield will cover the company's molecular assay for multiple myeloma.

The Multiple Myeloma Research Foundation is hoping that an open-access research portal containing detailed longitudinal clinical and genomic data from multiple myeloma patients will spur collaborative research that advances much needed molecularly-targeted treatments.

SkylineDx has acquired all assets from recently shuttered Skyline Diagnostics and will continue to develop and commercialize the latter's menu of microarray-based tests, BioArray News has learned.

Empire Genomics has discovered a genetic mutation that early studies suggest might be linked to increased response to a class of drugs called proteasome inhibitors.

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.